NEW ISSUE
Ischaemia with non-obstructive coronary arteries, OCT vs IVUS guidance in PCI; the ILUMIEN III and ILUMIEN IV trials…
January 20, 2021
1. Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China; 2. Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China
Percutaneous coronary intervention with drug-eluting stents (DES) has substantially improved clinical outcomes in patients with coronary artery disease, when compared with bare metal stents. However, permanent polymers of first-generation DES were linked with local inflammation, hypersensitivity reactions, and neoatherosclerosis, leading to an increased risk of very late stent thrombosis and DES failure at long-term follow-up. Recently, studies and meta-analyses have shown superiority of the new-generation DES with biodegradable or biocompatible polymer to previous-generation DES in terms of improved clinical outcomes1,2. However, whether the long-term clinical performance of these two types of DES after implantation is comparable remains debatable.
...
Sign in to read and download the full article
Forgot your password?No account yet? Sign up for free!
Create my pcr account Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Read next article
Will this trial change my practice? A new session format that seeks to link trial results to the patients we treat